Prevymis (letermovir) - Merck (MSD)
Influence of a three-month letermovir treatment on inflammation, immunity and HIV reservoir markers in people with HIV on antiretroviral therapy (ESCMID Global 2026) - Mar 6, 2026 - Pres time: Apr 21, 2026; 12:00 PM - 01:30 PM; Location: Poster area; No abstract available 
Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease • Inflammation
https://www.escmid.org/congress-events/escmid-global/programme/preliminary-programme/
 
Léna ROYSTON
 
Mar 6, 2026
 
Prev Next